Trelstar is owned by Verity.
Trelstar contains Triptorelin Pamoate.
Trelstar has a total of 1 drug patent out of which 0 drug patents have expired.
Trelstar was authorised for market use on 10 March, 2010.
Trelstar is available in injectable;intramuscular dosage forms.
The generics of Trelstar are possible to be released after 30 June, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US10166181||VERITY||Slow release pharmaceutical composition made of microgranules|| |
(6 years from now)
Market Authorisation Date: 10 March, 2010
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic